Amgen, Inc. (NASDAQ:AMGN) has earned a consensus recommendation of “Hold” from the twenty-six research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $194.21.
Several equities analysts recently weighed in on the stock. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price objective on the stock. in a report on Tuesday, March 6th. Mizuho reiterated a “buy” rating and issued a $200.00 target price on shares of Amgen in a report on Friday. Cann reiterated a “buy” rating on shares of Amgen in a report on Friday, June 8th. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Monday, June 18th. Finally, TheStreet upgraded shares of Amgen from a “c+” rating to a “b-” rating in a report on Friday, May 25th.
NASDAQ AMGN traded up $0.05 during trading hours on Tuesday, hitting $185.20. The company’s stock had a trading volume of 63,255 shares, compared to its average volume of 2,741,705. Amgen has a twelve month low of $163.31 and a twelve month high of $201.23. The firm has a market capitalization of $122.51 billion, a P/E ratio of 14.74, a P/E/G ratio of 2.30 and a beta of 1.38. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.88 and a quick ratio of 3.60.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $184.27, for a total value of $281,011.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 4,575 shares of company stock valued at $809,851. 0.19% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the business. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in Amgen by 110.7% in the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 340 shares during the last quarter. Braun Bostich & Associates Inc. acquired a new stake in Amgen in the first quarter valued at $113,000. WealthTrust Fairport LLC acquired a new stake in Amgen in the first quarter valued at $121,000. Cornerstone Advisors Inc. lifted its stake in Amgen by 76.5% in the first quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 316 shares during the last quarter. Finally, Taylor Hoffman Wealth Management acquired a new stake in Amgen in the fourth quarter valued at $127,000. Hedge funds and other institutional investors own 78.27% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.